-+ 0.00%
-+ 0.00%
-+ 0.00%

ResMed ties fiscal 2027 executive stock awards to adjusted EPS and revenue goals

PUBT·11/19/2026 21:18:40
Listen to the news
ResMed ties fiscal 2027 executive stock awards to adjusted EPS and revenue goals
  • ResMed approved fiscal year 2027 performance-based restricted stock unit awards for named executive officers on November 19, 2026.
  • The new design replaces absolute and relative total stockholder return measures with equally weighted annual adjusted EPS and adjusted revenue goals over three years.
  • A relative total stockholder return modifier ranges from 0.75 to 1.25, measured against S&P 500 companies over three years from grant.
  • Threshold, target and maximum performance yield payouts of 50%, 100% and 200%, respectively; total awards cannot exceed 200% of target.
  • Earned units vest upon compensation committee certification following the performance period, generally subject to continued service.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-468603), on November 19, 2026, and is solely responsible for the information contained therein.